portola pharmaceuticals stock price
645,483 +0.89 (2.50%) Updated May 3, 2019 04:00 PM ET. Last 30 Days. Use our historic performance chart to see real-time Portola Pharmaceuticals Inc stock price and the Portola Pharmaceuticals Inc news feed to help further your research before investing in fractional shares with any dollar amount you choose. At this early stage in the launch, there is considerable uncertainty and guesswork involved in projecting sales. Rare disease drugmaker Alexion will buy Portola Pharmaceuticals for $1.44 billion, the latest deal aimed at expanding its business beyond Soliris, its flagship product and top-selling therapy. The price target was set to $14.00 → $18.00. The following presents a detailed Portola Pharmaceuticals stock price history for your review. Portola Pharmaceuticals Inc. [NASDAQ: PTLA] loss 0.00% or 0.0 points to close at $17.94 with a heavy trading volume of 1150207 shares. Morgan Stanley does not see either upside or downside right now giving PTLA "Equal Weight" on their last update on May 08, 2020. Portola Pharmaceuticals Stock Price . Portola Pharmaceuticals Inc (NASDAQ: ... and the $15.17 average price target suggests a 124% upside from the current $6.76 trading price. Read more. PTLA / Portola Pharmaceuticals, Inc. / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment. Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) shareholders will doubtless be very grateful to see the share price up 152% in the last month.But over the last three years we’ve seen a quite serious decline. In the short term (2weeks), PTLA's stock price should underperform the market by -0.45%.During that period the price should oscillate between … Portola Stock News: Stock drops over 40% on Andexxa Revenue Announcement . Alexion will pay $18 per share for Portola, a roughly 130% premium over Portola's closing stock price on May 4. Add to portfolio. Stocks with similar financial metrics, market capitalization, and price volatility to Portola Pharmaceuticals Inc are KALA, NSTG, DVAX, ORGS, and BGMD. Portola Pharmaceuticals Stock Forecast NASDAQ:PTLA Price Target and Analyst Ratings. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. K ey Conclusion The outlook for Portola’s stock price in 2019 and 2020 will almost certainly driven by the sales progress of Andexxa. DDE w/Realtime (Monthly) Monthly Subscription. Free trial. Portola Pharmaceuticals Inc. [NASDAQ: PTLA] stock went on an upward path that rose over 0.17% on Wednesday, amounting to a one-week price increase of more than 0.06%. Price trends tend to persist, so it's worth looking at them when it comes to a share like Portola Pharmaceuticals Inc. Over the past six months, the relative strength of its shares against the market has been -33.23%. Over the last 12 months, PTLA stock dropped by -31.71%. for only . Free trial. Q4 Andexxa/Ondexxya sales will be ~$32M. After-Market: $36.46 (%) 5:22 PM ET. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer... | December 23, 2020 Market capitalization of Portola Pharmaceuticals (PTLA) Market cap: $1.41 B As of March 2021 Portola Pharmaceuticals has a market cap of $1.41 B.This makes Portola Pharmaceuticals the world's 3470th most valuable company by market cap according to our data. for only. Monthly Subscription. Under the terms of the merger agreement, a subsidiary of Alexion will commence a tender offer to acquire all of the outstanding shares of Portola’s common stock at a price of $18 per share in cash. $49.05. for only. PTLA stock forecast Our latest prediction for Portola Pharmaceuticals, Inc.'s stock price was made on the April 4, 2019 when the stock price was at 37.41$.. The stock price has decreased by -31.91% in the last 52 weeks. Portola Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops therapeutics for acute and chronic cardiovascular and autoimmune/inflammatory diseases. Price is a widely used stock evaluation measure. 18.03 0.00 (0.0%) Upgrade to Real-Time Afterhours (Closed) Best deals to access real time data! On January 9, 2020, Portola Pharmaceuticals announced that its preliminary unaudited Andexxa global net revenues came in far below estimates. Portola Pharmaceuticals (NASDAQ:PTLA) slumps 39% after hours in reaction to preliminary Q4 and 2019 results that are significantly below consensus. PTLA Price (Portola Pharmaceuticals stock price per share) $18.03 × PE Ratio Versus Sector. Alexion plans to fund the purchase with existing cash on hand and the transaction is expected to close in Q3/20. SOUTH SAN FRANCISCO, Calif., Aug. 13, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) today announced the pricing of its underwritten public offering of 8,035,715 shares of its common stock at a price to the public of $28.00 per share. Most Recent Rating . An important predictor of whether a stock price will go up is its track record of momentum. Portola Pharmaceuticals, Inc. (PTLA) (Delayed Data from NSDQ) $36.49 USD. Today, Portola Pharmaceuticals is trading at $19.32, which is a ~7.52% decline from yesterday’s close of $20.89 on December 10. Stock Price Statistics. Alexion is a global biopharmaceutical company focused on developing life-changing therapies for people living with rare disorders. Follow PTLA. Portola Pharmaceuticals, Inc. Stock Price Forecast, "PTLA" Predictons for2021 PTLA has attracted considerable attention from traders and investors, a scenario that has seen its volume jump … 2. Portola is now a wholly owned subsidiary of Alexion. 06-09 sec.gov - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. To help provide a sense of the short to long-term trend, included is an interactive Portola Pharmaceuticals stock chart which you can easily adjust to the time frame of your choosing (e.g. using the scroll bar or pinch and zoom on a touch screen). 11 )* Portola Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 737010108 … Alexion is paying a healthy premium over Portola’s closing price on Tuesday. The PE ratio measures the reported earnings of a company to its current stock price. Historical Ratings. Free trial. (See Orchard’s stock analysis at TipRanks.) According to the announcement, the company estimates Andexxa revenues to be around $28 million for the fourth quarter. The beta is 2.31, so PTLA's price volatility has been higher than the market average. (RTTNews) - Alexion Pharmaceuticals, Inc. (ALXN) and Portola Pharmaceuticals, Inc. (PTLA) have entered into a definitive merger agreement for Alexion to acquire Portola… Small Cap Pro. Monthly Subscription. The one-year Portola Pharmaceuticals Inc. stock forecast points to a potential upside of 7.67. A high-level overview of Portola Pharmaceuticals, Inc. (PTLA) stock. The tender offer for all of the outstanding shares of common stock of Portola at a price of $18.00 per share expired as scheduled, one minute following 11:59 p.m., New York City time, on July 1, 2020. The firms advised that "under the terms of the merger agreement, a subsidiary of Alexion will commence a tender offer to acquire all of the outstanding shares of Portola's common stock at a price of $18 per share in cash." Note: We will be using adjusted close prices for calculations. 36.49. Choose a Stash plan and set up your investment account in just a few minutes. AstraZeneca plc (/ ˌ æ s t r ə ˈ z ɛ n ə k ə /) is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters in Cambridge, England. It opened the trading session at $17.94, the shares rose to $17.96 and dropped to $17.92, the range by which the price of stock traded the whole day. In terms of volatility of its share price, PTLA is more volatile than 90.67% of stocks we're observing. $34.10. AstraZeneca has a portfolio of products for major diseases including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory and inflammation areas.. The first section will let you know the impact on $1000 in Portola Pharmaceuticals Inc (PTLA) due to the share price changes. Portola reported 2019 sales of $111.5 million for Andexxa, which is marketed as Ondexxya in Europe. VAT not included. Implied Volatility Surging for Portola Pharmaceuticals (PTLA) Stock … The last trading period has seen Portola Pharmaceuticals Inc. (PTLA) move -44.06% and 234.27% from the stock’s 52-week high and 52-week low prices respectively. The daily trading volume for Portola Pharmaceuticals Inc. (NASDAQ:PTLA) over the last session is 4.69 million shares. Indeed, the share price is down a tragic 57% in the last three years. The average equity rating for PTLA stock is currently 2.70, trading … $52.04. While earnings are easy to manipulate on the balance sheet, this ratio gives you a sense of what buyers are willing to pay for the stock—what they believe it will do in the future. Big Cap Pro. PTLA Stocks Year by Year Growth; Growth of 1000$ On PTLA Stock Vs S&P 500 Growth; Growth of 1000$ On PTLA Vs Gold ; 1 What would $1000 invested in Portola Pharmaceuticals Inc (PTLA) shares be worth now? In addition, the underwriters of the offering have been granted a 30-day option to purchase up to an additional 1,205,357 shares from Portola … Visit PTLA's SEC page to see the company's official filings.